









Markets
/
Stocks
/
nasdaq-iccc
/

ImmuCell Corp

ICCC

6.229USD

-0.071-1.12%

Market hours （ET）Quotes delayed by 15 min

56.35MMarket Cap

31.99P/E TTM



ImmuCell Corp

6.229

-0.071-1.12%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of ImmuCell Corp

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ImmuCell Corp's Score

Industry at a Glance

Industry Ranking

119 / 159

Overall Ranking

345 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ImmuCell Corp Highlights

StrengthsRisks

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 42.68% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 26.49M.

Overvalued

The company’s latest PE is 30.66, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.81M shares, decreasing 0.08% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 159.99K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.54.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 9.05, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 6.44M, representing a year-over-year increase of 17.76%, while its net profit experienced a year-over-year increase of 132.77%.

Score

Industry at a Glance

Previous score

9.05

Change



Financials

7.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.76

Key Metrics

Free cash flow

No Data

ImmuCell Corp's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.37, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 30.66, which is 10.48% below the recent high of 33.88 and 633.60% above the recent low of -163.62.

Score

Industry at a Glance

Previous score

7.37

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.77.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.99, which is equal to the Pharmaceuticals industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 6.90 and the support level at 5.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.30

Change

0.69

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.018

Sell

RSI(14)

51.608

Neutral

STOCH(KDJ)(9,3,3)

35.519

Neutral

ATR(14)

0.326

High Vlolatility

CCI(14)

35.793

Neutral

Williams %R

52.326

Neutral

TRIX(12,20)

-0.131

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

6.168

Buy

MA10

6.141

Buy

MA20

6.287

Sell

MA50

6.237

Sell

MA100

6.356

Sell

MA200

5.875

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 20.03%, representing a quarter-over-quarter decrease of 57.36%. The largest institutional shareholder is The Vanguard, holding a total of 308.70K shares, representing 3.41% of shares outstanding, with 34.81% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Pessin (Norman H)

644.02K

Rothschild (Jonathan E)

514.00K

SRK Capital, LLC

502.26K

Knudsen (Ejnar A III)

463.62K

Pessin (Sandra F)

401.82K

The Vanguard Group, Inc.

Star Investors

308.70K

+36.84%

Brigham (Michael F)

215.75K

Renaissance Technologies LLC

Star Investors

159.99K

+19.40%

Pessin (Brian L)

136.88K

Cresset Asset Management, LLC

132.00K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.02, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.